Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SPR | P35270 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19961309 | 0.87 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL2806341 | 0.82 | HSD11B1 (0.60) | RAB9ANPC1SMN1; SMN2ALDH1A1HSD11B1 | |
| SCHEMBL19961352 | 0.81 | MAPT (0.47) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL19961344 | 0.80 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL29640084 | 0.78 | HSD11B1 (0.59) | HSD11B1SPRUSP30KDM5APOLB | |
| SCHEMBL19961326 | 0.78 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL19961308 | 0.78 | ALDH1A1 (0.67) | RAB9AALDH1A1HSD11B1LMNASPR | |
| SCHEMBL4074303 | 0.76 | HSD11B1 (0.53) | HSD11B1SPRUSP30KDM5A | |
| SCHEMBL19961318 | 0.76 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL7301194 | 0.75 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072666-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | NOVALEX THERAPEUTICS INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072666-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | NOVALEX THERAPEUTICS INC (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072666-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | FAR1, TECR, ECI1 | RAB9A 1863/4885NPC1 210/4885SMN1; SMN2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.